Biogen to Halt Investment in Majority of Acquired Apellis Research Programs
BIIB sits 66% above its 52-week low of $121.05.
Summary
Biogen announced it will pause or terminate investment in the majority of research programs inherited from its recent acquisition of Apellis Pharmaceuticals. This strategic decision follows Biogen's completion of the $5.3 billion Apellis acquisition on May 14th. The move indicates a significant post-merger pipeline rationalization, potentially leading to R&D cost savings but also narrowing the future product pipeline from the Apellis deal. A small number of roles within the research organization have also been eliminated.
At the time of this announcement, BIIB was trading at $201.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.8B. The 52-week trading range was $121.05 to $206.67. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.